The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release
Chiara Saponaro(University of Pisa), Caroline Bonner(Inserm), François Pattou(Inserm), Marie‐Christine Vantyghem(Inserm), Nathalie Delalleau(Inserm), Ericka Moerman(Inserm), Julien Thévenet(Inserm), Audrey Quenon(Inserm), Gianni Pasquetti(Inserm), Anais Coddeville(Inserm), Mehdi Daoudi(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Julie Kerr‐Conte(Inserm), Yvan Martineau(Centre National de la Recherche Scientifique), Bart Staels(Inserm), Thomas Hübert(Inserm), Valéry Gmyr(Inserm)
Cited by 35
Related Papers
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
|Journal of Hepatology|2014|1.5k
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
|Journal of Biological Chemistry|1999|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
PPAR control of metabolism and cardiovascular functions
|Nature Reviews Cardiology|2021|901